Posted by Michael Wonder on 03 Feb 2021
Chinook receives rare paediatric disease designation from U.S. FDA for CHK-336 for treatment of primary hyperoxaluria
2 February 2021 - CHK-336 on track for Phase 1 clinical trial initiation in the second half of 2021.
Chinook Therapeutics today announced that the U.S. FDA has granted rare paediatric disease designation for CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A for primary hyperoxaluria.
